Stockscreener 앱 받기
7.03
0.85%
-0.06
시간 외 거래:
7.03
Aura Biosciences Inc 주식(AURA)의 최신 뉴스
Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock - 富途牛牛
The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k - simplywall.st
Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan
Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
AURA | Aura Biosciences, Inc. Common Executive Compensation - Quiver Quantitative
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com - Investing.com Nigeria
Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak - Stock Titan
Aura Biosciences Inc Actuals & Estimates (BOATS:AURA) - TradingView
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA) - TradingView
AURA Forecast — Price Target — Prediction for 2027 - TradingView
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Inc (AURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak - Stock Titan
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move - TipRanks
Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares - Stock Titan
Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding - Stock Titan
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
AURA Technical Analysis & Stock Price Forecast - Intellectia AI
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - The Manila Times
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment - Pluang
Aura Biosciences completes phase 3 enrollment for eye cancer drug - Investing.com
Eye cancer trial hits 108 patients as Aura tests new frontline therapy - Stock Titan
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Announcement Reaction - The Legal Advocate
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances - TradingView
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway - TradingView
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Ken Fisher's Aura Biosciences Inc(AURA) Holding History - GuruFocus
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AURA Director Holles Acquires 2.17M Stock Options on May 20, 2026 - Meyka
1.18%
2.48%
자본화:
|
볼륨(24시간):